Compare INSG & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSG | IBIO |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.2M | 56.0M |
| IPO Year | 2000 | 2009 |
| Metric | INSG | IBIO |
|---|---|---|
| Price | $4.33 | $0.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $13.67 | $5.69 |
| AVG Volume (30 Days) | 331.9K | ★ 780.5K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.71 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $313,832,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.21 | N/A |
| P/E Ratio | $35.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.58 | $0.79 |
| 52 Week High | $21.90 | $3.82 |
| Indicator | INSG | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 23.91 |
| Support Level | $3.96 | N/A |
| Resistance Level | $4.61 | $1.52 |
| Average True Range (ATR) | 0.27 | 0.08 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 57.10 | 9.49 |
Inseego Corp is involved in the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things, and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by application software and cloud services designed to enable customers to analyze data insights and configure and manage their hardware easily. It generates maximum revenue from the United States and Canada. The company also has a presence in Europe (including the United Kingdom).
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.